GHRP-6

What Is GHRP-2?

Growth Hormone–Releasing Peptide-2 (GHRP-2), known scientifically as pralmorelin, is a laboratory-synthesized peptide that functions as a ghrelin receptor agonist. As the first peptide identified within the growth hormone secretagogue class, it has served as a foundational compound in endocrine research. GHRP-2 has been evaluated in stage II clinical studies for growth-related disorders and remains under investigation for its effects on appetite, muscle metabolism, immune function, and sleep regulation. The peptide exhibits oral and sublingual bioactivity, enabling non-parenteral administration in controlled research environments.

GHRP-2 Structure

The molecular design of GHRP-2 consists of a compact peptide sequence optimized for receptor selectivity and functional stability. This configuration supports interaction with growth hormone signaling pathways while preserving biological activity during experimental use.

GHRP-2 Effects

1. Muscle Tissue Maintenance

Experimental studies in animal models have shown that GHRP-2 supports muscle tissue by promoting protein accumulation and suppressing protein degradation. Research indicates reduced expression of atrogin-1 and MuRF1, enzymes responsible for muscle catabolism. Activation of growth hormone and insulin-like growth factor-1 pathways further contributes to maintenance of lean tissue during adverse physiological conditions.

2. Appetite Enhancement

Administration of GHRP-2 has been consistently associated with increased food intake. Appetite stimulation has been examined in research contexts involving nutritional deficiency, where adequate caloric consumption is essential for metabolic stability and recovery.

3. Cardiac Cell Protection

In vitro and in vivo studies suggest that GHRP-2 reduces programmed cell death in cardiac cells subjected to stress. These effects may involve mitochondrial stabilization and receptor-mediated signaling unique to cardiovascular tissue.

4. Immune System Support

GHRP-2 has demonstrated stimulatory effects on the thymus, facilitating the production and diversification of T-cells necessary for adaptive immunity. This activity is particularly relevant given the natural decline in thymic function associated with aging.

5. Sleep Pattern Modification

Research findings indicate that GHRP-2 increases time spent in deep sleep stages while adjusting REM sleep proportions. These alterations are linked to improvements in sleep quality, cognitive function, and physiological restoration.

6. Analgesic Pathway Interaction

Pain reduction observed in animal studies occurred independently of growth hormone secretion, suggesting direct interaction with opioid receptors. GHRP-2 exhibits selectivity for receptors involved in analgesia, differentiating it from broad-spectrum opioid agents.

Research Use Disclaimer

Animal studies report favorable tolerability and bioavailability for GHRP-2; however, animal dosing data cannot be extrapolated to humans. This compound is intended exclusively for laboratory research and educational investigation and is not approved for human use.

Scientific Attribution

This document references published scientific literature and acknowledges contributions from Dr. Logan, M.D., and Dr. Jean-Alain Fehrentz. Citations are provided solely for scholarly recognition and do not indicate endorsement or commercial association.

Referenced Citations

1. R. Hu et al., "Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation," PloS One, vol. 11, no. 2, p. e0149461, 2016.
2. D. Yamamoto et al., "GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1," Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008.
3. L. T. Phung et al., "The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine," Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000.
4. B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men," J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005.
5. B. Laferrère, A. B. Hart, and C. Y. Bowers, "Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake," Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006.
6. G. Muccioli et al., "Growth hormone-releasing peptides and the cardiovascular system," Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000.
7. V. Bodart et al., "Identification and characterization of a new growth hormone-releasing peptide receptor in the heart," Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999.
8. D. D. Taub, W. J. Murphy, and D. L. Longo, "Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways," Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010.
9. G. Gopinadh et al., "Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man," Neuroendocrinology, vol. 66, no. 4, pp. 278–286, Oct. 1997.
10. P. Zeng et al., "Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice," Peptides, vol. 55, pp. 103–109, May 2014.
11. Moulin, A. , Ryan, J. , Martinez, J. and Fehrentz, J. (2007), Recent Developments in Ghrelin Receptor Ligands. ChemMedChem, 2: 1242-1259.